Genetic Risk Factor Found for Rare Frontotemporal Dementia Form

A newly identified genetic factor is offering a crucial foothold in understanding a rare and devastating form of frontotemporal dementia, a condition that often affects individuals while they are still professionally active. Researchers at VIB and Antwerp University, publishing their findings in Nature Genetics, have pinpointed a repeat expansion in the GOLGA8A gene as a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions, or aFTLD-U.

Frontotemporal dementia (FTD) encompasses a group of disorders that primarily impact personality, behavior, language and decision-making abilities – distinct from the memory loss typically associated with Alzheimer’s disease. While less common overall than Alzheimer’s, FTD is a leading cause of dementia onset at younger ages. Professor Rosa Rademakers (VIB-UAntwerp Center for Molecular Neurology), whose career has focused on the genetic basis of FTD, explains that the early symptoms – often perceived as personality changes or stress – can delay diagnosis, impacting careers and relationships.

A Rare Subtype, Now Within Reach

The specific form under investigation, aFTLD-U, is particularly challenging to study due to its rarity. It’s characterized by specific pathological features, including the presence of ubiquitin-positive inclusions, and often presents with behavioral changes in individuals as young as their thirties or forties. A definitive diagnosis, still, traditionally requires post-mortem examination. Distinguishing subtypes like aFTLD-U is becoming increasingly important, as different forms of FTD may respond differently to potential therapies.

Rademakers’ research, supported by a one-million euro Generet Prize for Rare Disease Research from the King Baudouin Foundation, initially faced skepticism. The sporadic nature of aFTLD-U – meaning it doesn’t typically run in families – suggested a limited genetic component. However, her persistence paid off, leading to this significant breakthrough.

The Power of Global Collaboration and Advanced Sequencing

The key to unlocking this genetic puzzle lay in a collaborative, international effort to gather samples from enough patients with aFTLD-U to conduct a robust genetic analysis. Combining Rademakers’ extensive collection with advances in sequencing technology allowed the team to identify the repeat expansion in the GOLGA8A gene.

Dr. Wouter De Coster, a postdoctoral researcher in Rademakers’ lab, explains the methodology: “First, we ran a genome-wide association study in 59 pathologically confirmed aFTLD-U cases and thousands of controls. Next, long-read sequencing data enabled us to identify a repeat expansion in an intron of GOLGA8A.” This long-read sequencing was crucial, as traditional short-read methods often struggle to resolve complex genetic regions like GOLGA8A, which exists in multiple copies within the genome.

The strength of the association was particularly striking. “We rarely witness an association of this strength,” De Coster notes. “Even in much larger studies of common disorders, signals typically aren’t this pronounced.”

What Does This Mean for Patients and Future Research?

The discovery of this genetic risk factor, present in nearly 60% of aFTLD-U cases, represents a fundamental step forward in understanding the disease’s biology. While the precise functional consequences of the repeat expansion are still under investigation, researchers believe it plays a critical role in disease development. The lab is now focused on unraveling how this repeat affects gene regulation and cellular processes in vulnerable brain regions.

It’s important to note that the repeat expansion doesn’t account for all cases of aFTLD-U. Rademakers suggests that other genetic factors, potentially in other complex regions of the genome, may contribute to the disease in some patients. The research doesn’t yet explain why some individuals carrying the repeat expansion develop the disease while others do not.

Despite these remaining questions, the identification of this genetic factor provides a crucial starting point for developing targeted therapies. It similarly underscores the potential for genetic contributions to diseases previously considered sporadic. As Rademakers states, identifying a concrete genetic factor can enable earlier and more precise diagnosis and may ultimately support therapies that target the underlying mechanism.

Expanding the Scope: Polygenic Risk Scores and Alzheimer’s Disease

This discovery arrives alongside broader advancements in understanding the genetic architecture of neurodegenerative diseases. Recent research, highlighted in Nature, explores the transferability of polygenic risk scores – which combine the effects of many genetic variants – for Alzheimer’s disease across different ancestral populations. This work is crucial for ensuring that genetic risk assessment tools are equitable and accurate for all individuals.

The Role of Machine Learning in Genetic Discovery

The field is also increasingly leveraging the power of machine learning to analyze complex genetic data. Nature reports on the application of machine learning techniques in Alzheimer’s disease genetics, offering the potential to identify novel genetic risk factors and predict disease progression.

Looking Ahead: Continued Research and Clinical Implications

The identification of the GOLGA8A repeat expansion is not the finish of the story, but rather a pivotal step forward. Ongoing research will focus on understanding the functional consequences of the repeat, identifying additional genetic factors contributing to aFTLD-U, and developing targeted therapies. For individuals and families affected by this rare form of dementia, this discovery offers a renewed sense of hope and a pathway towards more effective diagnosis and treatment. Anyone concerned about potential symptoms of FTD should consult with a qualified healthcare professional for evaluation and guidance.